M Taune1, P Ustero2, S Hiashiri2, K Huang2, P Aia3, L Morris4, S Main2, G Chan2, P du Cros2, S S Majumdar2. 1. Daru General Hospital, Daru, Western Province, Papua New Guinea. 2. Burnet Institute, Melbourne, Victoria, Australia. 3. National TB Program, Port Moresby, Papua New Guinea. 4. Provincial Health Office, Daru, Western Province, Papua New Guinea.
Abstract
SETTING: Bedaquiline (BDQ) was introduced in the multi-drug-resistant tuberculosis (MDR-TB) programme in Daru in remote Papua New Guinea in 2015, along with a core package of active drug-safety monitoring (aDSM). OBJECTIVE: To assess interim results and safety of BDQ for the treatment of MDR-TB from 1 July 2015 to 31 December 2017. DESIGN: A retrospective cohort analysis of routine programme data. RESULTS: Of 277 MDR-TB patients, 77 (39%) received BDQ with a total of 8 serious adverse events including 5 (6.5%) deaths, of which 1 (1.3% QTcF prolongation, grade 3) was attributable to BDQ. Of 200 (61%) patients who did not receive BDQ, there were 17 (9%) deaths. Completeness of monitoring for the BDQ group was 90% for >5 electrocardiograms and 79% for ⩾2 cultures. In the interim result indicator analysis at month 6 in the BDQ and non-BDQ groups, there were respectively 0% and 1% lost to follow-up; 6.5% and 8.5% who died; 94% and 91% in care; and 92% and 96% with negative culture among those monitored. CONCLUSION: Early experience in Daru shows BDQ is safe and feasible to implement with aDSM with good interim effectiveness supporting the rapid adoption and scale-up of the 2019 WHO MDR-TB treatment guidelines in the programme and in similar remote settings.
SETTING: Bedaquiline (BDQ) was introduced in the multi-drug-resistant tuberculosis (MDR-TB) programme in Daru in remote Papua New Guinea in 2015, along with a core package of active drug-safety monitoring (aDSM). OBJECTIVE: To assess interim results and safety of BDQ for the treatment of MDR-TB from 1 July 2015 to 31 December 2017. DESIGN: A retrospective cohort analysis of routine programme data. RESULTS: Of 277 MDR-TB patients, 77 (39%) received BDQ with a total of 8 serious adverse events including 5 (6.5%) deaths, of which 1 (1.3% QTcF prolongation, grade 3) was attributable to BDQ. Of 200 (61%) patients who did not receive BDQ, there were 17 (9%) deaths. Completeness of monitoring for the BDQ group was 90% for >5 electrocardiograms and 79% for ⩾2 cultures. In the interim result indicator analysis at month 6 in the BDQ and non-BDQ groups, there were respectively 0% and 1% lost to follow-up; 6.5% and 8.5% who died; 94% and 91% in care; and 92% and 96% with negative culture among those monitored. CONCLUSION: Early experience in Daru shows BDQ is safe and feasible to implement with aDSM with good interim effectiveness supporting the rapid adoption and scale-up of the 2019 WHO MDR-TB treatment guidelines in the programme and in similar remote settings.
Authors: Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley Journal: N Engl J Med Date: 2009-06-04 Impact factor: 91.245
Authors: A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley Journal: Antimicrob Agents Chemother Date: 2012-03-05 Impact factor: 5.191
Authors: V Cox; G Brigden; R H Crespo; E Lessem; S Lynch; M L Rich; B Waning; J Furin Journal: Int J Tuberc Lung Dis Date: 2018-04-01 Impact factor: 2.373
Authors: N Ndjeka; F Conradie; K Schnippel; J Hughes; N Bantubani; H Ferreira; G Maartens; D Mametja; G Meintjes; X Padanilam; E Variava; A Pym; Y Pillay Journal: Int J Tuberc Lung Dis Date: 2015-08 Impact factor: 2.373
Authors: L Guglielmetti; C Hewison; Z Avaliani; J Hughes; N Kiria; N Lomtadze; N Ndjeka; S Setkina; A Shabangu; W Sikhondze; A Skrahina; N Veziris; J Furin Journal: Int J Tuberc Lung Dis Date: 2017-02-01 Impact factor: 2.373
Authors: M Bonnet; M Bastard; P du Cros; A Khamraev; K Kimenye; S Khurkhumal; A Hayrapetyan; D Themba; A Telnov; E Sanchez-Padilla; C Hewison; F Varaine Journal: Int J Tuberc Lung Dis Date: 2016-02 Impact factor: 2.373
Authors: J Furin; E Alirol; E Allen; K Fielding; C Merle; I Abubakar; J Andersen; G Davies; K Dheda; A Diacon; K E Dooley; G Dravnice; K Eisenach; D Everitt; D Ferstenberg; A Goolam-Mahomed; M P Grobusch; R Gupta; E Harausz; M Harrington; C R Horsburgh; C Lienhardt; D McNeeley; C D Mitnick; S Nachman; P Nahid; A J Nunn; P Phillips; C Rodriguez; S Shah; C Wells; B Thomas-Nyang'wa; P du Cros Journal: Int J Tuberc Lung Dis Date: 2016-03 Impact factor: 2.373
Authors: Arnold Bainomugisa; Evelyn Lavu; Stenard Hiashiri; Suman Majumdar; Alice Honjepari; Rendi Moke; Paison Dakulala; Grant A Hill-Cawthorne; Sushil Pandey; Ben J Marais; Chris Coulter; Lachlan Coin Journal: Microb Genom Date: 2018-01-04